Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611699 · ClinicalTrials.gov registry record · Phase 4
Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients
A Phase 4 study of COPD, sponsored by Gary L. Pierce.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03611699 is a Phase 4 study of COPD that has completed, run by Gary L. Pierce. The registered enrollment target is 15 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03611699, a Phase 4 study of COPD, has completed, sponsored by Gary L. Pierce.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the acute effects of a long-acting bronchodilator on pulmonary function, vascular function and muscle sympathetic nerve activity in individuals with COPD. Individuals will be recruited from previous pulmonary research cohorts at The University of Iowa hospitals and clinics. Individuals that are interested in the study and are deemed eligible to participate will have a total of 3 visits to the laboratory, which includes the screening and consent (visit 1) that will last approximately 1 hour. Visits 2 and 3 are experimental visits and will be more extensive (\~4 hours). Participants will be randomized to receive either a long-acting bronchodilator or a placebo inhaler at the first experimental visit, followed by either the placebo inhaler or the long-acting bronchodilator at the second experimental visit. Assessments of pulmonary function, vascular function (via non-invasive, well-established techniques), and muscle sympathetic nerve activity will be performed at both experimental visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Umeclidinium / Vilanterol Dry Powder Inhaler
Study Locations (1)
Iowa
- The University of Iowa Hospital and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611699
The ClinicalTrials.gov registry entry for NCT03611699 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The listed sponsor is Gary L. Pierce, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03611699 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03611699 about?
NCT03611699 is a clinical study titled "Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients". The goal of this study is to evaluate the acute effects of a long-acting bronchodilator on pulmonary function, vascular function and muscle sympathetic nerve activity in individuals with COPD. Individuals will be recruited from previous pulmonary research cohorts at The University of Iowa hospitals ...
What is the current status of trial NCT03611699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2019-01-24. Estimated completion is 2020-04-01.
What conditions does trial NCT03611699 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT03611699?
The interventions under investigation include: Placebo (DRUG), Umeclidinium / Vilanterol Dry Powder Inhaler (DRUG).
Who is sponsoring clinical trial NCT03611699?
This trial is sponsored by Gary L. Pierce, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03611699 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
COMPLETED · Phase 4
-
Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 4
-
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COMPLETED · Phase 4
-
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.